

Cholamandalam Inv & Fin

BSE SENSEX
58,650

S&P CNX
17,470



Stock Info

Bloomberg	CIFC IN
Equity Shares (m)	820
M.Cap.(INRb)/(USDb)	466.2 / 6.2
52-Week Range (INR)	668 / 345
1, 6, 12 Rel. Per (%)	-8/-13/24
12M Avg Val (INR M)	2280
Free float (%)	48.4

Financials Snapshot (INR b)

Y/E March	2022E	2023E	2024E
Total Income	56.4	61.3	69.3
PPP	37.3	39.6	44.7
PAT	19.6	23.6	27.3
EPS (INR)	24.0	28.8	33.3
EPS Gr. (%)	29.7	20.2	15.7
BV (INR)	138	164	194

Valuations

NIM (%)	7.2	7.3	7.3
C/I ratio (%)	33.8	35.4	35.5
RoAA (%)	2.6	2.8	2.9
RoE (%)	18.8	19.1	18.6
Payout (%)	9.2	8.7	8.3

Valuations


P/E (x)	23.7	19.7	17.0
P/BV (x)	4.1	3.5	2.9
Div. Yield (%)	0.4	0.4	0.5

Shareholding pattern (%)

As On	Sep-21	Jun-21	Sep-20
Promoter	51.6	51.6	51.6
DII	22.5	21.8	29.1
FII	17.9	18.9	11.3
Others	8.0	7.7	7.9

FII Includes depository receipts

Stock Performance (1-year)



CMP: INR568

TP: INR700 (+23%)

Buy

Going strong despite supply-side headwinds

Asset quality exhibiting steady improvement

- Cholamandalam Investment & Finance (CIFIC) is a franchise we have always felt very strongly about owing to its ability to play different credit cycles better than its peers. We particularly like that even within Vehicle Finance, it very tactically turns Underweight/Overweight in different product segments to deliver industry-leading growth and the most benign credit costs.
- Understandably, CIFIC's disbursements in the recent quarter (2Q) were propped up by strong disbursements in the LAP segment. However, one also needs to understand that the LAP franchise has been strengthened significantly in the last two years.
- Its performance in disbursements (including LAP and Home Loans) has been superior v/s peers, while collection efficiency (CE) has consistently been 100%+ for the past few months. Macro indicators, such as e-way bills (despite the seasonal decline seen in Nov'21 post the festive season) and GST collections, also indicate strong recovery.
- The company, very strategically, keeps working on its product mix to ensure healthy blended yields. Going forward, while there would be only a minor benefit in cost of borrowings, coupled with the normalization of excess balance sheet liquidity, this would lead to stable margins.
- CIFIC posted a 20% AUM CAGR over FY16–21, while the normalized RoA profile (adjusted for one-off COVID provisions) improved to ~2.6% (in FY22E) from ~2.0% (in FY15). CIFIC is well-diversified across product segments as well as geographies. Importantly, it has delivered the best asset quality among peers across credit cycles as well as in times when the external environment has been tough. The impact of newer variants / COVID waves is a known unknown; however, the levels of provisions carried by CIFIC today give us comfort that any newer disruption in the economy should not lead to outsized credit costs. The stock trades at 3.5x FY23E P/BV, above its 10-year average of 2.5x. Given CIFIC's ability to deliver industry-leading growth in the loan book (CAGR of 13% over FY22–24E) – coupled with its strong asset quality (expected credit cost of ~1% over FY23–24E) and consequently healthy RoE of ~19% – we believe it would continue to command premium valuations relative to its listed peers in Vehicle Finance. Maintain Buy, with TP of INR700 (3.9x Sep'23E BVPS).

COVID, chip shortage, excessive south rainfall will impact growth in FY22

OEMs suggest the availability of chips is gradually increasing, and normal production could resume by Mar'22. Commentaries from vehicle financiers also suggest supply-side issues could significantly ease by the end of the current fiscal. Our recent channel checks suggest disbursements (and even collections) for vehicle financiers were impacted in Nov'21 due to excessive rainfall in some of the states in southern India. Disbursements for vehicle financiers in 3QFY22 would, therefore, be potentially lower than earlier targeted. However, this could well be due to vehicle sales (and thus financing) being postponed to 4QFY22. With the expectation of recovery in OEM sales in 4QFY22, CIFIC would continue to deliver above-average disbursement growth in the foreseeable future. While we

Research Analyst: Abhijit Tibrewal (Abhijit.Tibrewal@MotilalOswal.com)

Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com);

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

expect AUM growth to be modest at ~6% YoY in FY22 (due to impacted disbursements), it should improve to ~11% in FY23E and subsequently to the mid-teen levels from FY24E.

Underweight/Overweight in different vehicle product segments helps maintain optimum product mix

The share of HCVs in the AUM mix has declined from ~20% to 10% over the past three years, while that in disbursements has declined from ~15% to ~4%. The company made this strategic choice around three years ago – while this led to some impact on growth for CIFIC, it helped improve overall yields and return ratios. During this period, it saw the proportion of tractor financing in the disbursement mix almost doubling to 13% in FY21 (from 7% in FY18), led by robust demand for tractors. Commentary from CIFIC suggests it once again anticipates demand for HCVs to pick up, led by spending on infrastructure and real estate. Given CIFIC's presence in all the vehicle segments, it very tactically turns Underweight/Overweight in different product segments to maintain an optimum product mix, feeding into a strong return profile.

Provisions healthy; expect gradual improvement in asset quality to feed into normalized credit costs from FY23

CIFIC's 'stressed' pool (Stage 2 + Stage 3 loans) has increased 8.7pp to 18.8% over the last two quarters (vis-à-vis a ~11% increase in 30+dpd loans for MMFS over the same period). CIFIC's total provision buffer [ECL/EAD] stood at 4.1% and has been increased by ~50bp in 1HFY22 (up 225bp since the pandemic outbreak). While the loan book did exhibit stress with the advent of the second COVID wave, CIFIC has managed to rein in some of the asset quality deterioration in 2QFY22. Moreover, we expect steady improvement in Stage 3 to ~5% by Mar'22 and further improvement to ~4% and ~3% levels by FY23E and FY24E respectively. We also believe that this would be supported by improved LAP asset quality – the company would be able to leverage SARFAESI for the resolution of stressed advances more effectively.

We believe CIFIC has been conservative in provisioning and is well provided for. We should now see credit costs normalize to run-rate levels (~1%) unless the new COVID variant leads to renewed medical emergencies and localized lockdowns in the country.

Expect stable spreads and margins even as liquidity remains marginally elevated in current environment

A large portion of the benefits on incremental cost of borrowings (CoB) is already reflected in CIFIC's blended CoB. The company has effectively leveraged the debt capital markets for its incremental borrowings in the last year. We expect yields to be largely stable and any minor yield pressure (~10bp) to be mitigated by commensurate decline in blended CoB. In the current backdrop and with the resurgence of COVID (new variant), we expect the liquidity buffer to remain marginally elevated through FY22. Thereafter, the management would probably look to bring this down to normalized levels of 6–7% of the balance sheet.

Strategic direction for the next decade

Under the chairmanship of Mr Vellayan Subbiah, investors have been trying to understand the strategic direction the company would take and how it would evolve over the next 5–10 years. CIFIC has been highly conservative in guiding investors over the next phase of its evolution. It is currently doing various pilots to understand the different product/customer segments in which to expand its presence over the next five years. It aims to have a presence in the Vehicle, SME, and Consumer Finance ecosystems. While some investors may believe CIFIC is not doing enough on the technological/digital front, we believe it is already doing pilots and would divulge further information when it is appropriately convinced about entering any new product segments.


Great combination of industry-leading growth and RoE; Maintain Buy

CIFIC is likely to continue to grow faster than peers over the medium term, in our opinion. Its asset quality performance and the consequent credit cost would be significantly better v/s peers. **With RoE of ~19% over the medium term, its return ratios are among the best.** The company is well-capitalized with a CRAR of 19.6% and would not need any equity growth capital over the near term.

Given CIFIC's ability to deliver industry-leading growth in the loan book – coupled with its strong asset quality (credit cost of ~1% over FY23–24E) and consequently healthy RoE of ~19% – we believe CIFIC would continue to command premium valuations relative to its listed peers in Vehicle Finance. We maintain a Buy rating, with TP of INR700 (3.9x Sep'23E BVPS). Key risks include a) a potential third COVID wave leading to localized lockdowns and disruptions in the economy and b) a prolonged shortage of semiconductor chips leading to continued supply-side issues in passenger vehicles and small commercial vehicles.


Story in charts

Exhibit 1: Expect disbursement growth of ~20% each over FY23E and FY24E




Source: MOFSL, Company


Exhibit 2: AUM growth should pick up over next two years




Source: MOFSL, Company

Exhibit 3: CIFIC poised to deliver healthy AUM growth relative to peers


Source: MOFSL, Company

Exhibit 4: Expect steady spreads and margins


Source: MOFSL, Company

Exhibit 5: Cost ratios to remain at current levels, driven by investments in distribution and technology


Source: MOFSL, Company

Exhibit 6: Credit costs to normalize to run-rate of ~100bp


Source: MOFSL, Company

Exhibit 7: Expect 22% PAT CAGR over FY21–24

Source: MOFSL, Company

Exhibit 8: Expect healthy RoE of ~19% over medium term

Source: MOFSL, Company

Exhibit 9: RoE profile of CIFIC relatively better v/s peers (%)

Source: MOFSL, Company

Exhibit 10: DuPont analysis

%	2016	2017	2018	2019	2020	2021	2022E	2023E	2024E
Interest Income	15.1	13.9	13.1	12.8	12.9	12.8	12.3	12.4	12.4
Interest Expended	7.9	7.1	6.7	7.1	7.6	6.6	5.9	5.9	5.9
Net Interest Income	7.2	6.8	6.4	5.7	5.4	6.2	6.4	6.5	6.5
Other Operating Income	1.1	0.9	0.7	1.0	1.3	0.9	1.0	0.9	0.8
Net Income	8.3	7.7	7.1	6.7	6.7	7.1	7.4	7.4	7.4
Operating Expenses	3.3	3.2	2.8	2.5	2.6	2.3	2.5	2.6	2.6
Operating Income	5.0	4.5	4.3	4.2	4.1	4.9	4.9	4.8	4.7
Provisions/write offs	1.7	1.0	0.8	0.6	1.5	1.9	1.4	0.9	0.8
PBT	3.4	3.5	3.5	3.6	2.6	2.9	3.5	3.8	3.9
Tax	1.2	1.2	1.2	1.3	0.9	0.8	0.9	1.0	1.0
Reported PAT	2.2	2.3	2.3	2.3	1.7	2.2	2.6	2.8	2.9
Leverage	7.6	8.0	8.5	9.1	8.5	7.8	7.3	6.7	6.4
RoE	16.6	18.2	19.7	21.2	14.7	17.1	18.8	19.1	18.6


Source: MOFSL, Company

Exhibit 11: Largely unchanged estimates

INR B	Old Est.			New Est.			% change		
	FY22	FY23	FY24	FY22	FY23	FY24	FY22	FY23	FY24
NII (incl. assignments)	49.0	54.8	62.6	48.9	53.8	61.4	-0.3	-1.7	-1.8
Other Income	7.5	7.5	7.9	7.5	7.5	7.9	0.0	0.0	0.0
Total Income	56.5	62.3	70.4	56.4	61.3	69.3	-0.2	-1.5	-1.6
Operating Expenses	19.1	21.7	24.6	19.1	21.7	24.6	0.0	0.0	0.0
Operating Profits	37.5	40.6	45.8	37.3	39.6	44.7	-0.4	-2.3	-2.4
Provisions	10.9	9.6	8.1	10.9	7.9	7.9	-0.3	-18.0	-2.7
PBT	26.5	31.0	37.6	26.4	31.8	36.8	-0.4	2.5	-2.3
Tax	6.8	8.0	9.7	6.8	8.2	9.4	-0.4	2.5	-2.3
PAT	19.7	23.0	28.0	19.6	23.6	27.3	-0.4	2.5	-2.3
AUM	744	834	966	740	821	946	-0.5	-1.5	-2.0
Loans	699	792	917	696	780	899	-0.5	-1.5	-2.0
Borrowings	677	750	869	673	739	852	-0.5	-1.5	-2.0
NIM	7.2	7.3	7.3	7.2	7.3	7.3			
Credit Cost	1.5	1.2	0.9	1.5	1.0	0.9			
RoA on AUM	2.6	2.8	2.9	2.6	2.8	2.9			
RoE	18.9	18.7	19.1	18.8	19.1	18.6			


Source: MOFSL, Company

Exhibit 12: PB trend (1yr forward)



Source: MOFSL, Company

Exhibit 13: PE trend (1yr forward)



Source: MOFSL, Company

Financials and valuation

Income Statement						(INR m)		
Y/E March	2017	2018	2019	2020	2021	2022E	2023E	2024E
Interest Income	43,717	51,862	64,962	78,417	88,772	94,109	1,02,570	1,17,126
Interest Expenses	22,308	26,593	35,887	45,922	45,759	45,222	48,733	55,679
Net Interest Income	21,409	25,268	29,075	32,495	43,013	48,887	53,836	61,446
Change (%)	14.8	18.0	15.1	11.8	32.4	13.7	10.1	14.1
Income from assignments	2,103	0	867	2,473	0	0	0	0
Other Operating Income	776	2,931	4,090	5,637	6,388	7,500	7,460	7,851
Total Income	24,295	28,203	34,039	40,607	49,437	56,401	61,312	69,312
Change (%)	13.4	16.1	20.7	19.3	21.7	14.1	8.7	13.0
Total Operating Expenses	10,133	11,153	12,696	15,776	15,834	19,081	21,690	24,628
Change (%)	19.9	10.1	13.8	24.3	0.4	20.5	13.7	13.5
Employee Expenses	4,027	5,368	5,906	6,550	7,494	8,618	9,824	11,199
Business Origination Expenses	1,784	775	1,525	2,398	2,242	2,511	2,812	3,093
Other Operating Expenses	4,323	5,010	5,265	6,828	6,099	7,953	9,054	10,335
Operating Profit	14,162	17,051	21,344	24,831	33,603	37,320	39,621	44,684
Change (%)	9.1	20.4	25.2	16.3	35.3	11.1	6.2	12.8
Total Provisions	3,106	3,037	3,112	8,973	13,218	10,890	7,851	7,923
% of Operating Profit	21.9	17.8	14.6	36.1	39.3	29.2	19.8	17.7
PBT	11,056	14,014	18,232	15,857	20,384	26,431	31,770	36,762
Tax Provisions	3,868	4,831	6,370	5,334	5,235	6,788	8,159	9,441
Tax Rate (%)	35.0	34.5	34.9	33.6	25.7	25.7	25.7	25.7
PAT	7,187	9,183	11,862	10,524	15,149	19,643	23,611	27,320
Change (%)	26.4	27.8	29.2	-11.3	44.0	29.7	20.2	15.7
Proposed Dividend	547	1,016	1,016	1,662	1,640	1,804	2,050	2,255

Balance Sheet						(INR m)		
Y/E March	2017	2018	2019	2020	2021	2022E	2023E	2024E
Share Capital	1,564	1,564	1,564	1,640	1,640	1,640	1,640	1,640
Reserves & Surplus	40,971	49,105	59,880	80,079	93,962	1,11,430	1,32,570	1,57,172
Net Worth for Equity Shareholders	42,535	50,669	61,445	81,718	95,602	1,13,070	1,34,210	1,58,812
Borrowings	3,02,001	3,83,303	5,05,667	5,50,054	6,37,300	6,73,489	7,39,075	8,51,764
Change (%)	33.8	26.9	31.9	8.8	15.9	5.7	9.7	15.2
Total Liabilities	3,50,372	4,40,897	5,74,263	6,39,930	7,45,484	7,86,559	8,73,285	10,10,576
Investments	697	729	729	729	16,188	17,107	18,773	21,636
Change (%)	4.6	4.7	0.0	0.0	2,120.0	5.7	9.7	15.2
Loans	3,32,244	4,22,532	5,26,223	5,54,027	6,58,393	6,95,692	7,80,135	8,99,084
Change (%)	27.9	27.2	24.5	5.3	18.8	5.7	12.1	15.2
Net Fixed Assets	1,417	1,646	1,759	2,839	2,294	1,162	848	421
Total Assets	3,50,372	4,40,897	5,74,263	6,39,930	7,45,484	7,86,559	8,73,285	10,10,576

E: MOFSL Estimates

Financials and valuation

Ratios	(%)							
Y/E March	2017	2018	2019	2020	2021	2022E	2023E	2024E
Spreads Analysis (%)								
Avg. Yield on Loans	14.8	13.7	13.7	14.5	14.6	13.9	13.9	14.0
Avg Cost of Funds	8.5	7.8	8.1	8.7	7.7	6.9	6.9	7.0
Spread of loans	6.3	6.0	5.6	5.8	6.9	7.0	7.0	7.0
NIM (on loans)	7.2	6.7	6.1	6.0	7.1	7.2	7.3	7.3
Profitability Ratios (%)								
RoE	18.2	19.7	21.2	14.7	17.1	18.8	19.1	18.6
RoA	2.3	2.3	2.3	1.7	2.2	2.6	2.8	2.9
Int. Expended / Int.Earned	51.0	51.3	55.2	58.6	51.5	48.1	47.5	47.5
Other Inc. / Net Income	3.2	10.4	12.0	13.9	13.0	13.3	12.2	11.3
Efficiency Ratios (%)								
Op. Exps. / Net Income	41.7	39.5	37.3	38.9	32.0	33.8	35.4	35.5
Empl. Cost/Op. Exps.	39.7	48.1	46.5	41.5	47.3	45.2	45.3	45.5
Asset-Liability Profile (%)								
Loans/Borrowings Ratio	110.0	110.2	104.1	100.7	103.3	103.3	105.6	105.6
Net NPAs to Net Adv.	3.2	2.3	1.6	2.2	2.3	3.1	2.2	1.8
Assets/Equity	8.2	8.7	9.3	7.8	7.8	7.0	6.5	6.4
Valuations								
Book Value (INR)	54.4	64.8	78.6	99.7	116.6	137.9	163.7	193.7
BV Growth (%)	16.2	19.1	21.2	26.9	17.0	18.3	18.7	18.3
Price-BV (x)					4.9	4.1	3.5	2.9
EPS (INR)	9.2	11.7	15.2	12.8	18.5	24.0	28.8	33.3
EPS Growth (%)	26.3	27.7	29.1	-15.4	44.0	29.7	20.2	15.7
Price-Earnings (x)					30.7	23.7	19.7	17.0
Dividend per share	1.1	1.3	1.3	1.7	2.0	2.2	2.5	2.8
Dividend Yield (%)					0.4	0.4	0.4	0.5
E: MOFSL Estimates								

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com. CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai- 400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579; PMS: INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.: 022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.